HALOZYME THERAPEUTICS, INC. (HALO) Operating cash flow 2016–2025
HALOZYME THERAPEUTICS, INC. (HALO) annual operating cash flow history from SEC filings — net cash provided by operating activities each fiscal year.
$651.6MFY2025 · since FY2016: -$50.4M → $651.6M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | $651.6M | +36.0% |
| FY2024 | $479.1M | +23.3% |
| FY2023 | $388.6M | +61.8% |
| FY2022 | $240.1M | -19.8% |
| FY2021 | $299.4M | +440.0% |
| FY2020 | $55.5M | +164.9% |
| FY2019 | -$85.4M | -72.6% |
| FY2018 | -$49.5M | -136.9% |
| FY2017 | $134.1M | +366.1% |
| FY2016 | -$50.4M | — |
Source: SEC XBRL filings · For reference only · Not investment advice